Skip to main content
Top
Published in: Osteoporosis International 4/2012

01-04-2012 | Original Article

Gender differences for initiating teriparatide therapy: Baseline Data from the Direct Assessment of Nonvertebral Fracture in the Community Experience (DANCE) study

Authors: M. Wong, X. Wan, V. Ruff, K. Krohn, K. Taylor

Published in: Osteoporosis International | Issue 4/2012

Login to get access

Abstract

Summary

The prospective, observational Direct Assessment of Nonvertebral Fracture in the Community Experience (DANCE) study shows that, among patients with risk factors for osteoporosis, women are more likely to be screened and to receive appropriate treatment than men. There needs to be greater awareness that osteoporosis affects both men and women.

Introduction

The prospective, observational DANCE study evaluated teriparatide use in the mainland USA and Puerto Rico in patients with osteoporosis in a community setting. This analysis compares baseline characteristics of women and men that may contribute to differences in initiation of teriparatide therapy.

Methods

Investigators prescribed teriparatide 20 μg/day subcutaneous injection for ≤24 months to 3,698 patients (3,342 women, 356 men) whom they considered appropriate candidates for therapy. Study entry was guided by product labeling. Specific timing and frequency of office visits were not mandated. Treatment decisions were based on the clinical judgment of study investigators and local standards of care.

Results

At baseline, similar proportions of women and men had prior fragility fractures (57% and 59%, respectively) and comorbid conditions that increase fracture risk (83% and 84%, respectively). Women were older than men (mean age 68 vs. 65 year; P < 0.0001) and more likely to have received prior osteoporosis therapy (88% vs. 62%; P < 0.0001). Investigators prescribed teriparatide more often for women than men based on general frailty (21% vs. 16%; P = 0.0151), low body mass index (17% vs. 10%; P = 0.0005), and an inadequate response (58% vs. 36%; P < 0.0001) or intolerance to previous therapy (23% vs. 12%; P < 0.0001). Chronic glucocorticoid therapy was the reason investigators cited most frequently for initiating therapy more often in men than in women (17% vs. 10%; P < 0.0001)

Conclusions

These results suggest that patients’ gender may influence the reasons physicians initiate teriparatide therapy in a community setting.
Literature
1.
go back to reference Teng GG, Curtis JR, Saag KG (2009) Quality health care gaps in osteoporosis: how can patients, providers, and the health system do a better job? Curr Osteoporos Rep 7:27–34PubMedCrossRef Teng GG, Curtis JR, Saag KG (2009) Quality health care gaps in osteoporosis: how can patients, providers, and the health system do a better job? Curr Osteoporos Rep 7:27–34PubMedCrossRef
3.
go back to reference Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726–1733PubMedCrossRef Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726–1733PubMedCrossRef
5.
go back to reference Campion JM, Maricic MJ (2003) Osteoporosis in men. Am Fam Physician 67:1521–1526PubMed Campion JM, Maricic MJ (2003) Osteoporosis in men. Am Fam Physician 67:1521–1526PubMed
6.
go back to reference Sacco SM, Ward WE (2010) Revisiting estrogen: efficacy and safety for postmenopausal bone health. J Osteoporos 2010:708931PubMed Sacco SM, Ward WE (2010) Revisiting estrogen: efficacy and safety for postmenopausal bone health. J Osteoporos 2010:708931PubMed
7.
go back to reference Geusens P, Dinant G (2007) Integrating a gender dimension into osteoporosis and fracture risk research. Gend Med 4(Suppl B):S147–S161PubMedCrossRef Geusens P, Dinant G (2007) Integrating a gender dimension into osteoporosis and fracture risk research. Gend Med 4(Suppl B):S147–S161PubMedCrossRef
8.
go back to reference Adler R, Curtis J, Weinstein RS, Saag KG (2010) Glucocorticoid-induced osteoporosis. In: Marcus R, Feldman D, Nelson DA, Rosen CJ (eds) Osteoporosis, 3rd edn. Elsevier, New York, pp 1135–1166CrossRef Adler R, Curtis J, Weinstein RS, Saag KG (2010) Glucocorticoid-induced osteoporosis. In: Marcus R, Feldman D, Nelson DA, Rosen CJ (eds) Osteoporosis, 3rd edn. Elsevier, New York, pp 1135–1166CrossRef
11.
go back to reference Curtis JR, McClure LA, Delzell E et al (2009) Population-based fracture risk assessment and osteoporosis treatment disparities by race and gender. J Gen Intern Med 24:956–962PubMedCrossRef Curtis JR, McClure LA, Delzell E et al (2009) Population-based fracture risk assessment and osteoporosis treatment disparities by race and gender. J Gen Intern Med 24:956–962PubMedCrossRef
12.
go back to reference Center JR, Bliuc D, Nguyen TV, Eisman JA (2007) Risk of subsequent fracture after low-trauma fracture in men and women. JAMA 297:387–394PubMedCrossRef Center JR, Bliuc D, Nguyen TV, Eisman JA (2007) Risk of subsequent fracture after low-trauma fracture in men and women. JAMA 297:387–394PubMedCrossRef
13.
go back to reference Miller PD, Silverman SL, Gold DT et al (2006) Rationale, objectives and design of the Direct Analysis of Nonvertebral Fracture in the Community Experience (DANCE) study. Osteoporos Int 17:85–90PubMedCrossRef Miller PD, Silverman SL, Gold DT et al (2006) Rationale, objectives and design of the Direct Analysis of Nonvertebral Fracture in the Community Experience (DANCE) study. Osteoporos Int 17:85–90PubMedCrossRef
14.
go back to reference Orwoll ES, Scheele WH, Paul S et al (2003) The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9–17PubMedCrossRef Orwoll ES, Scheele WH, Paul S et al (2003) The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9–17PubMedCrossRef
15.
go back to reference Saag KG, Shane E, Boonen S, Marin F et al (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357:2028–2039PubMedCrossRef Saag KG, Shane E, Boonen S, Marin F et al (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357:2028–2039PubMedCrossRef
16.
go back to reference Saag KG, Zanchetta JR, Devogelaer JP et al (2009) Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 60:3346–3355PubMedCrossRef Saag KG, Zanchetta JR, Devogelaer JP et al (2009) Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 60:3346–3355PubMedCrossRef
17.
go back to reference Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441PubMedCrossRef Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441PubMedCrossRef
20.
go back to reference Feldstein AC, Nichols G, Orwoll E et al (2005) The near absence of osteoporosis treatment in older men with fractures. Osteoporos Int 16:953–962PubMedCrossRef Feldstein AC, Nichols G, Orwoll E et al (2005) The near absence of osteoporosis treatment in older men with fractures. Osteoporos Int 16:953–962PubMedCrossRef
21.
go back to reference Papaioannou A, Kennedy CC, Ioannidis G et al (2008) The osteoporosis care gap in men with fragility fractures: the Canadian Multicentre Osteoporosis study. Osteoporos Int 19:581–587PubMedCrossRef Papaioannou A, Kennedy CC, Ioannidis G et al (2008) The osteoporosis care gap in men with fragility fractures: the Canadian Multicentre Osteoporosis study. Osteoporos Int 19:581–587PubMedCrossRef
22.
go back to reference Cooper C, Campion G, Melton LJ III (1992) Hip fractures in the elderly: a world-wide projection. Osteoporos Int 2:285–289PubMedCrossRef Cooper C, Campion G, Melton LJ III (1992) Hip fractures in the elderly: a world-wide projection. Osteoporos Int 2:285–289PubMedCrossRef
23.
go back to reference Adler RA (2006) The need for increasing awareness of osteoporosis in men. Clin Cornerstone 8(Suppl 3):S7–S13PubMedCrossRef Adler RA (2006) The need for increasing awareness of osteoporosis in men. Clin Cornerstone 8(Suppl 3):S7–S13PubMedCrossRef
24.
go back to reference Rao SS, Budhwar N, Ashfaque A (2010) Osteoporosis in men. Am Fam Physician 82:503–508PubMed Rao SS, Budhwar N, Ashfaque A (2010) Osteoporosis in men. Am Fam Physician 82:503–508PubMed
25.
go back to reference Qaseem A, Snow V, Shekelle P et al (2008) Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians. Ann Intern Med 148:680–684PubMed Qaseem A, Snow V, Shekelle P et al (2008) Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians. Ann Intern Med 148:680–684PubMed
26.
go back to reference Orwoll E, Blank JB, Barrett-Connor E et al (2005) Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study—a large observational study of the determinants of fracture in older men. Contemp Clin Trials 26:569–585PubMedCrossRef Orwoll E, Blank JB, Barrett-Connor E et al (2005) Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study—a large observational study of the determinants of fracture in older men. Contemp Clin Trials 26:569–585PubMedCrossRef
27.
go back to reference Lewis CE, Ewing SK, Taylor BC et al (2007) Predictors of non-spine fracture in elderly men: the MrOS study. J Bone Miner Res 22:211–219PubMedCrossRef Lewis CE, Ewing SK, Taylor BC et al (2007) Predictors of non-spine fracture in elderly men: the MrOS study. J Bone Miner Res 22:211–219PubMedCrossRef
28.
go back to reference Grossman JM, Gordon R, Ranganath VK et al (2010) American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res 62:1515–1526CrossRef Grossman JM, Gordon R, Ranganath VK et al (2010) American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res 62:1515–1526CrossRef
29.
go back to reference Van Staa TP, Leufkens HG, Abenhaim L et al (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993–1000PubMedCrossRef Van Staa TP, Leufkens HG, Abenhaim L et al (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993–1000PubMedCrossRef
Metadata
Title
Gender differences for initiating teriparatide therapy: Baseline Data from the Direct Assessment of Nonvertebral Fracture in the Community Experience (DANCE) study
Authors
M. Wong
X. Wan
V. Ruff
K. Krohn
K. Taylor
Publication date
01-04-2012
Publisher
Springer-Verlag
Published in
Osteoporosis International / Issue 4/2012
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-011-1725-8

Other articles of this Issue 4/2012

Osteoporosis International 4/2012 Go to the issue